Minimum daily balance

CV Sciences, Inc. Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
ERC, CARES Act, Nicotine, OTCQB, PDT, Minimum daily balance, Japan Patent Office, Sale, Softgel, EBITDA, Acquisition, Patent, SAN, Growth, Relaxation, RSU, Pharmaceutical industry, Video game, Retail, CBD

SAN DIEGO, May 15, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.

Key Points: 
  • SAN DIEGO, May 15, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.
  • "Our first quarter gross margins exceeded our expectations and we are encouraged by improvements we have made to reduce operating expense.
  • Sales for first quarter 2023 were $4.1 million, a decrease of 7% from $4.4 million for the first quarter 2022.
  • The Company had negative adjusted EBITDA for the first quarter of 2023 of $0.2 million, compared to negative adjusted EBITDA of $2.5 million in the first quarter of 2022.

CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels

Retrieved on: 
Tuesday, March 21, 2023
Balance, Cannabinoid, OTCQB, Minimum daily balance, Military personnel, SAN, Occupation, The Non-GMO Project, THC, Safety, Dietary supplement, Softgel, CBD

SAN DIEGO, March 21, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Daily Balance THC-Free Gummies and Softgels. These new additions to the +PlusCBD™ product portfolio are now available for purchase at +PlusCBD.

Key Points: 
  • The +PlusCBD™Daily Balance THC Free line offers a daily-use supplement that provides the wellness benefits of CBD without THC and other cannabinoids.
  • +PlusCBD™Daily Balance THC-Free Gummies and Softgels are made with CV Sciences' 99.9% pure CBD isolate, expertly crafted in concentrations that help consumers overcome intense challenges to their everyday mental and physical wellbeing.
  • "Sometimes, consumers just want to experience the relaxing effects of CBD without THC," said Joseph Dowling, CEO of CV Sciences.
  • The +PlusCBD™ Daily Balance THC Free line is intended for daily use to help consumers reach their personal wellness goals.

Novus Announces New Illiquid Portfolio Capabilities for Asset Allocators and Managers

Retrieved on: 
Wednesday, September 29, 2021
Minimum daily balance, AUM, PNL, PE, Shock, DNA, Control panel, Horse, Gentilini, Communication, CEO, Acquisition, Growth, Geography, McKinsey & Company, COVID-19, Intelligence, Aggregation, ESMA, Investment, Wine, GLOBE, Cryptocurrency, Asset management, Bank, Financial adviser

New York, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Novus Partners, a portfolio intelligence company servicing both asset allocators and managers, today announced significant updates to its platform as it relates to the ingestion and analysis of deep portfolio data.

Key Points: 
  • New York, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Novus Partners, a portfolio intelligence company servicing both asset allocators and managers, today announced significant updates to its platform as it relates to the ingestion and analysis of deep portfolio data.
  • The tool lets clients dynamically configure and model how cash flows and portfolio exposures are projected across all funds within a clients portfolio.
  • Fund Attribution: With this enhancement, Novus clients are able to measure how much of their portfolio performance comes from asset allocation versus manager selection decisions.
  • Novus is a portfolio intelligence company that solves the unique data and analytics challenges facing capital allocators and hedge fund managers, offering best-in-class solutions for investors.